Global Liquid Biopsy Market Size
The global liquid biopsy market is poised for substantial growth, with an estimated market size of US$ 15.45 billion by 2033, up from US$ 3.72 billion in 2024. This represents a robust CAGR of 17.14% from 2025 to 2033. The surge in demand stems from the increasing need for non-invasive cancer diagnostics, advancements in biomarker technologies, and the growing adoption of personalized medicine.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=liquid-biopsy-market-p.php
Global Liquid Biopsy Market Outlook
A liquid biopsy is a non-invasive diagnostic method that analyzes biological fluids like blood to detect cancer and other diseases. Unlike traditional tissue biopsies, liquid biopsies utilize circulating biomarkers such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and exosomes found in the bloodstream. These innovative techniques provide real-time insights into tumor dynamics, enabling early detection, disease monitoring, and treatment evaluation.
Key Advantages:
- Reduced risk and quicker results compared to tissue biopsies.
- Real-time tracking of tumor progression and response to therapy.
- Applications beyond oncology, including prenatal testing and monitoring chronic conditions.
Key Growth Drivers in the Liquid Biopsy Market
- Rising Incidence of Cancer and Chronic Diseases
The increasing prevalence of cancer globally is a major growth driver. Liquid biopsies facilitate early detection and treatment planning, particularly for cancers like lung, breast, and colorectal cancers. By 2024, 2 million new cancer cases and over 600,000 cancer-related deaths are anticipated in the U.S. alone.
- Advancements in Biomarker Technology
Innovations like next-generation sequencing (NGS) and ctDNA analysis have enhanced the sensitivity and specificity of liquid biopsies. These technologies allow clinicians to identify actionable mutations and track disease in real-time. For example, in August 2024, Hitachi High-Tech partnered with Gencurix to advance molecular diagnostics in cancer.
- Shift Toward Non-Invasive Diagnostics
Liquid biopsies align with patient-centric care by offering minimally invasive solutions, especially for advanced-stage cancer patients. The shift toward home-based and outpatient diagnostic settings further supports their adoption.
Related Report:
Regional Insights
United States
The U.S. dominates the global liquid biopsy market due to a high cancer incidence rate and advanced healthcare infrastructure. The FDA's clearance of liquid biopsy technologies and robust investments in R&D are key growth drivers. In February 2024, Myriad Genetics acquired assets from Intermountain Health, enhancing its portfolio of liquid biopsy tests.
Germany
Germany leads Europe in adopting liquid biopsy technologies, supported by a strong biotechnology sector and medical research ecosystem. The launch of innovative products, such as PAXgene Urine Liquid Biopsy Set by PreAnalytiX in September 2024, demonstrates its commitment to precision diagnostics.
China
China's rapid market expansion is fueled by rising cancer cases and government support for advanced diagnostics. The approval of sunvozertinib by China’s National Medical Products Administration in August 2023 exemplifies its growing prominence in the global market.
Brazil
As Latin America’s largest economy, Brazil is a leader in liquid biopsy adoption. Investments in modernizing healthcare and increasing cancer awareness are driving growth.
Competitive Landscape
Key Players and Recent Developments:
- F. Hoffmann-La Roche Ltd.
- Partnered with LCRF in 2022 to advance lung cancer research.
- FDA-approved liquid biopsy tests for NSCLC (2020).
- Launched advanced digital PCR systems and custom cancer research tools in 2022.
- Received FDA approval for Guardant360 CDx in 2023, a breakthrough in breast cancer diagnostics.
- Launched TruSight Oncology 500 ctDNA v2 in 2023, enabling comprehensive genomic profiling.
- Introduced QIAseq targeted cfDNA ultra panels in 2023 to enhance cancer research capabilities.
Segmentation Analysis
By Product:
- Kits & Reagents
- Platforms & Instruments
- Services
By Application:
- Cancer Therapeutics
- Reproductive Health
- Other Therapeutics
By Circulating Biomarkers:
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
By End-User:
- Hospitals
- Diagnostic Laboratories
- Point-of-Care Testing
By Region:
- Americas: U.S., Canada, Brazil
- Europe: Germany, UK, France
- Asia-Pacific: China, India, Japan
- Middle East & Africa
About Us - Renub Research
Renub Research is a premier Market Research and Advisory company with over 15 years of experience in Business-to-Business Global Market Research, Business Surveys, and Management Consulting. We provide a wide range of specialized business research services designed to help organizations make informed decisions and achieve their highest potential.
We work closely with our clients to understand the challenges they face and offer actionable insights to address these challenges. Our services are aimed at identifying the necessary changes and strategic adjustments needed for companies to succeed in today’s competitive market. Our clients include leading organizations from a wide range of industries such as Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecommunications & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.
At Renub Research, we provide our clients with detailed and accurate market data to support decision-making based on both information and knowledge. Our firm is recognized for delivering comprehensive industry solutions that aid consultants, bankers, and executives in formulating effective business strategies and making sound management decisions.
Our team comprises skilled professionals with expertise across various fields, including finance, marketing, human resources, biotechnology, pharmaceuticals, IT, environmental science, and more. The insights derived from our studies form the foundation for crucial management decisions, such as strategies, organizational structure, technology adoption, and mergers and acquisitions.
We take pride in supporting top global players, providing not only IT solutions but also comprehensive market trend analysis and opportunities. Our research reports offer critical tools for managers in today’s competitive global economy, featuring information and insights, analysis and understanding, as well as forecasts and estimations to guide decision-making
Comments